Catalent Shareholders Overwhelmingly Approve Acquisition

Catalent, Inc. ("Catalent") has announced the approval of its pending acquisition by Novo Holdings A/S ("Novo Holdings") at a special meeting of stockholders. The transaction involves Novo Holdings acquiring all outstanding shares of Catalent for $63.50 per share in cash. The preliminary count of the voting results from the special meeting indicates that 99.2% of ballots cast were in favor of the proposed transaction.

Catalent anticipates filing the final voting results for its special meeting with the Securities and Exchange Commission, after certification by Catalent’s inspector of elections. The transaction is expected to close towards the end of calendar year 2024, subject to customary closing conditions and receipt of required regulatory approvals, with no financing contingency.

Catalent, Inc. is a global leader in enabling pharma, biotech, and consumer health partners to optimize product development, launch, and full life-cycle supply for patients worldwide. In its 2023 fiscal year, the company generated nearly $4.3 billion in revenue, and its workforce of nearly 18,000 includes more than 3,000 scientists and technicians. Catalent helps accelerate over 1,500 partner programs and launches over 150 new products every year, with its flexible manufacturing platforms at over 50 global sites supplying approximately 70 billion doses of nearly 8,000 products annually. As a result of these announcements, the company's shares have moved 0.3% on the market, and are now trading at a price of $53.73. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.